Replimune announces priority review for its melanoma treatment
Source: SeekingAlpha
2025-01-21 08:41:38 ET
More on Replimune Group
- Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
- Replimune climbs after updates on lead drug
- Replimune Group GAAP EPS of -$0.68 beats by $0.09
- Seeking Alpha’s Quant Rating on Replimune Group
- Historical earnings data for Replimune Group
Read the full article on Seeking Alpha
For further details see:
Replimune announces priority review for its melanoma treatment
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
10.23% G/L:
$5.125 Last:
2,115,475 Volume:
$4.90 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
